There is no exact dose-conversion formula from semaglutide to tirzepatide. The FDA-approved switching approach is to stop semaglutide, wait about 1 week, and start tirzepatide at 2.5 mg weekly regardless of your prior semaglutide dose. Titrate up every 4 weeks through 5, 7.5, 10, 12.5, and 15 mg as tolerated. Informal clinical equivalence — semaglutide 1 mg ≈ tirzepatide 5 to 7.5 mg after titration; semaglutide 2.4 mg ≈ tirzepatide 10 to 15 mg — is useful as a rough guide but is not a dose-interchangeability statement. Expect 2 to 4 weeks of re-adaptation after each step.
Why There Is No Clean Conversion
Semaglutide and tirzepatide are different molecules:
- Semaglutide: single GLP-1 receptor agonist peptide
- Tirzepatide: dual GLP-1 and GIP receptor agonist peptide
- Different binding affinities, potencies, and receptor mechanisms
- Different pharmacokinetic profiles
- Dosing scales and units are not interchangeable (mg does not map 1:1)
- No head-to-head pharmacokinetic study comparing them at each dose
Standard FDA-Approved Switch Protocol
- Stop semaglutide after your last scheduled weekly dose
- Wait approximately 1 week before starting tirzepatide
- Start tirzepatide 2.5 mg weekly — the labeled starter dose
- After 4 weeks at 2.5 mg, titrate to 5 mg weekly
- After 4 weeks at 5 mg, titrate to 7.5 mg weekly (if further effect is needed)
- Continue stepping up every 4 weeks: 10, 12.5, 15 mg
- Hold at the lowest effective dose (target A1C or weight-loss goal met)
Informal Equivalence Observed in Practice
| Prior Semaglutide Dose | Tirzepatide Dose Often Reached After Titration | Approximate Timeline |
|---|---|---|
| 0.25 mg (starter) | 2.5 mg (starter) | Start at 2.5 mg |
| 0.5 mg | 5 mg | Week 5–8 |
| 1.0 mg (common T2D maintenance) | 5 to 7.5 mg | Week 5–12 |
| 1.7 mg | 7.5 to 10 mg | Week 9–16 |
| 2.0 mg (Ozempic max) | 10 mg | Week 13–16 |
| 2.4 mg (Wegovy max) | 10 to 15 mg | Week 13–20 |
These are practice-based observations, not FDA-validated conversions. Your endocrinologist may shorten titration for well-tolerated semaglutide users, but labels require the 2.5 mg restart.
Why the Titration Restart Is Required
- GI tolerance: starting fresh at 2.5 mg lets the gut adapt to the new molecule’s GI effects
- Dual receptor mechanism: tirzepatide’s GIP component can produce different nausea patterns than semaglutide alone
- Dose-potency differences: tirzepatide 5 mg is often more potent than semaglutide 1 mg for weight loss
- Safety margin: reduces risk of severe GI side effects during transition
- FDA label compliance: labeled starter dose is 2.5 mg regardless of prior GLP-1 exposure
Practical Tips for the Transition
- Complete your current semaglutide supply before starting tirzepatide — do not overlap
- Keep a food and symptom log for the first 4 weeks
- Expect appetite to return during the 2.5 mg starter phase — budget for slight transient regain
- Stay hydrated (2 to 3 liters daily) to offset GI side effects
- Maintain protein intake (1.2 to 1.6 g/kg body weight)
- If severe nausea during titration, request an extended step (hold for 8 weeks instead of 4)
- Re-check A1C and weight at weeks 8 and 16 after switch
- Review dose with your clinician at each step
What to Expect Physiologically
- Weeks 1–4 (2.5 mg): mild nausea resembling starter dose; appetite partial restoration from semaglutide level
- Weeks 5–8 (5 mg): appetite suppression returning; nausea typically mild
- Weeks 9–12 (7.5 mg): for many, this matches or exceeds prior semaglutide effect
- Weeks 13–16 (10 mg): further weight loss; close monitoring of response
- Weeks 17–20 (12.5 mg): intensification; most patients have reached target
- Weeks 21+ (15 mg): maximum dose; stay if still improving, otherwise plateau
When to Switch the Other Way (Tirzepatide to Semaglutide)
- Tirzepatide shortage or availability issues (most compounded tirzepatide ended early 2025)
- Severe GI intolerance to tirzepatide
- Insurance change that covers semaglutide but not tirzepatide
- Patient preference for familiar drug
Same principle applies — restart semaglutide at 0.25 mg regardless of prior tirzepatide dose, titrate every 4 weeks. Expect some transient regain during re-titration.
Side Effect Differences to Anticipate
| Side Effect | Semaglutide | Tirzepatide |
|---|---|---|
| Nausea | 15–25% | 25–30% |
| Diarrhea | 10–15% | 15–20% |
| Constipation | 15–25% | 10–15% |
| Vomiting | 5–8% | 8–12% |
| Injection site reaction | 2–3% | 3–5% |
| Weight loss (max dose) | 13–15% | 15–21% |
| A1C reduction (max dose) | 1.6–1.8% | 1.8–2.4% |
Common Mistakes During the Switch
- Starting tirzepatide at a dose equal to prior semaglutide (e.g., 10 mg to match 1 mg semaglutide) — severe GI reaction likely
- Stopping semaglutide and immediately taking tirzepatide without the 1-week pause
- Expecting full weight-loss effect during the 2.5 mg starter phase
- Not adjusting other medications (insulin, sulfonylureas) — hypoglycemia risk
- Giving up at week 4 because effect is less than prior semaglutide
- Titrating up every 2 weeks instead of 4 weeks
Related Reading
See our guides on treatment options, reversibility, and A1C levels.
The Bottom Line
There is no exact semaglutide-to-tirzepatide dose conversion. Switch by stopping semaglutide, waiting about a week, and starting tirzepatide at 2.5 mg weekly, then titrating every 4 weeks through 5, 7.5, 10, 12.5, and 15 mg as tolerated. Informal practice-based equivalence — semaglutide 1 mg ≈ tirzepatide 5 to 7.5 mg; semaglutide 2.4 mg ≈ tirzepatide 10 to 15 mg — is a rough planning guide. Expect 2 to 4 weeks of GI adaptation at each step, possible 1 to 3 pounds of transient regain during the starter phase, and matching or exceeding prior semaglutide effects by week 12 to 16 on most patients. Work closely with your endocrinologist through the transition.
